FDA Claims Short-Term Success For Pre-Market Device Reforms
This article was originally published in The Gray Sheet
Executive Summary
With many of its 510(k) and science reforms at least partially implemented, CDRH says it is seeing tangible, positive results. The device center cites a turnaround on multiple measures of review performance following the lows of 2010.
You may also be interested in...
Consistency Among CDRH Review Divisions Improves, But Industry Wants More
A new report from the California Healthcare Institute shows a positive convergence of performance among FDA’s device review divisions, but the biomedical industry group thinks more policy reforms that build on models from the best performing CDRH divisions and branches might be warranted.
FDA Reports Declining 510(k) Times, And Other Improvements
The most recent user-fee program trends report from FDA, with data current to March 31, 2014, shows improvements in 510(k) review metrics.
Device Trends To Watch In 2013
The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, are providing the industry with some momentum going into 2013.